8.79

0.48% -0.07

Prothena Corp Plc (PRTA)

Overview News Price History Option Chain Financials Why PRTA Down? Discussions Forecast

Prothena Corp Plc stock is traded at $8.79, with a volume of 186.43K. It is down -0.48% in the last 24 hours and up +1.82% over the past month. Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Previous Close:

$8.86

Open:

$8.84

24h Volume:

186.43K

Relative Volume:

0.33

Market Cap:

$451.77M

Revenue:

$57.94M

Net Income/Loss:

$-151.18M

P/E Ratio:

-3.1263

EPS:

-2.8116

Net Cash Flow:

$-86.56M

1W Performance:

-3.32%

1M Performance:

+1.82%

6M Performance:

-1.59%

1Y Performance:

+6.88%

1-Day Range:

$8.77

$9.075

1-Week Range:

$8.77

$9.365

52-Week Range:

$7.73

$11.80

Prothena Corp Plc Stock (PRTA) Company Profile

Name

Prothena Corp Plc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

011-353-1-236-2500

Address

77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2

Employee

Twitter

@ProthenaCorp

Next Earnings Date

2026-08-03

Latest SEC Filings

PRTA's Discussions on Twitter

Compare PRTA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRTA Prothena Corp Plc	8.80	454.85M	57.94M	-151.18M	-86.56M	-2.8116
VRTX Vertex Pharmaceuticals Inc	515.52	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.79	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.63	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.26	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.16	39.31B	5.76B	514.49M	1.10B	4.4813

Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-25	Downgrade	BofA Securities	Neutral → Underperform
May-27-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-27-25	Downgrade	Jefferies	Buy → Hold
May-27-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Jan-30-24	Downgrade	BofA Securities	Buy → Neutral
Dec-12-23	Initiated	Deutsche Bank	Buy
Apr-24-23	Initiated	SVB Securities	Outperform
Jan-27-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral
Jun-08-21	Reiterated	Oppenheimer	Outperform
May-26-21	Initiated	Citigroup	Buy
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-12-21	Upgrade	Jefferies	Hold → Buy
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy
Dec-07-20	Initiated	H.C. Wainwright	Buy
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform
Nov-19-19	Upgrade	Evercore ISI	In-line → Outperform
May-21-18	Downgrade	Barclays	Equal Weight → Underweight
Apr-23-18	Downgrade	Jefferies	Buy → Hold
Apr-05-18	Reiterated	Barclays	Overweight
Nov-20-17	Downgrade	Wedbush	Outperform → Neutral
Sep-29-17	Reiterated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-11-17	Initiated	Jefferies	Buy
Apr-12-17	Initiated	Cantor Fitzgerald	Overweight
Apr-12-17	Initiated	Piper Jaffray	Overweight
Mar-02-17	Initiated	Instinet	Buy
Dec-21-16	Initiated	SunTrust	Buy
Nov-03-16	Initiated	Deutsche Bank	Buy
Aug-04-16	Reiterated	Barclays	Overweight
May-13-16	Initiated	Barclays	Overweight
Feb-19-16	Reiterated	Wedbush	Outperform
Jan-21-16	Initiated	Credit Suisse	Outperform

View All

Prothena Corp Plc Stock (PRTA) Latest News

Aug 11, 2026

HC Wainwright Issues Positive Estimate for Prothena Earnings - MarketBeat

Aug 11, 2026

Aug 08, 2026

Prothena (PRTA) Stock Shrugs Off Revenue Drop As Pipeline Stakes Rise - Sahm

Aug 08, 2026

Aug 07, 2026

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - Yahoo Finance

Aug 07, 2026

Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat

Aug 07, 2026

Aug 06, 2026

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights - marketscreener.com

Aug 06, 2026

FMR LLC discloses 13.8% Prothena (PRTA) ownership; key fund holds 6.4% - Stock Titan

Aug 06, 2026

Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA - MarketBeat

Aug 06, 2026

Jul 31, 2026

Prothena (NASDAQ:PRTA) Insider Anne Evans Kingston Sells 7,662 Shares of Stock - marketbeat.com

Jul 31, 2026

Jul 30, 2026